Discontinued cardiovascular drugs in 2015

Expert Opinion on Investigational Drugs

Volumn 25, Issue 9, 2016, Pages 1093-1101

  Zhao, Hong ping ^a   Dai, Yan ^a   Xiang, Bing ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

beraprost sodium; CI 201; ciclosporin; evacetrapib; icatibant acetate; PF 05285401; TAK 272

Indexed keywords

BERAPROST; CARDIOVASCULAR AGENT; CI 201; CYCLOSPORIN A; EVACETRAPIB; ICATIBANT; PF 05285401; TAK 272; UNCLASSIFIED DRUG; NEW DRUG;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT WITHDRAWAL; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DESIGN; PRECLINICAL STUDY; TREATMENT FAILURE;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; TREATMENT FAILURE;

EID: 84979521066     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1212836     Document Type: Article

References (44)

1. WHO. Cardiovascular disease; 2015 [cited 2015 Mar27]. Available from:http://www.who.int/cardiovascular_diseases/en/.
2. The Pharmaprojects Database, Informa UK Plc; [cited 2016 Jan]. Available from:http://www.pharmaprojects.com.
3. Thomson Reuters Integrity, Thomson Reuters Canada Plc; [cited 2016 Jun]. Available from:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_home.util_home.
4. Takeda. ×. Pipeline; 2010 [cited 2016 Jan28]. Available from:http://www.takeda.com/investor-information/results/pdf/2010/qr2010_full_d10_en.pdf.
5. Takeda. III. Pipeline1; 2015 Oct 30 [cited 2016 Jan28]. Available from:http://www.takeda.com/research/files/pipeline_20151030_en.pdf.
6. Athersys. MultiStem programs; [cited 2016 Feb5]. Available from:http://www.athersys.com/msOverview.cfm.
7. Athersys. Athersys receives orphan drug designation for multiStem in graft vs. host disease; 2010 Sep 21 [cited 2016 Feb5]. Available from:http://www.athersys.com/releasedetail.cfm?releaseid=509426.
8. Athersys. Athersys’ multistem(R) stem cell therapy receives orphan drug designation in europe for prevention of graft-versus-host disease; 2013 Dec 17 [cited 2016 Feb5]. Available from:http://www.athersys.com/releasedetail.cfm?ReleaseID=814256.
9. Biospace. Athersys, Inc. Receives orphan drug designation for multistem in Hurler’s syndrome; 2012 Jul 10 [cited 5Feb 2016]. Available from:http://www.biospace.com/news_story.aspx?StoryID=266251&full=1.
10. Athersys. Healios and Athersys enter into regenerative medicine partnership for treatment of stroke using multistem(R) Therapy; 2016 Jan 08 [cited 2016 Feb6]. Available from:http://www.athersys.com/releasedetail.cfm?ReleaseID=949491.
11. Athersys. Athersys Announces Positive Results from Phase I Study of Multistem(R) in Heart Attack Patients; 2010 Jul 28 [cited 2016 Jan30]. Available from:http://files.shareholder.com/downloads/ATHERSYS/1428250267x0x391025/16B0D9E5-ECB6-4204-8EA5-C01227422673/ATHX_News_2010_7_28_General_Releases.pdf.
12. Athersys. Athersys announces results from phase 2 study of multistem(R) cell therapy for treatment of ischemic stroke; 2015 Apr 17 [cited 2016 Feb6]. Available from:http://www.athersys.com/releasedetail.cfm?ReleaseID=907107.
13. Athersys. Athersys reports third quarter 2015 results; 2015 Nov 5 [cited 2016 Feb6]. Available from:http://www.athersys.com/releasedetail.cfm?ReleaseID=941050.
14. Athersys. Other programs; [cited 2016 Feb6]. Available from:http://www.athersys.com/msOtherPrograms.cfm.
15. Pfizer, Athersys, Inc. A study to investigate the safety and possible clinical benefit of multistem(r) in patients with moderate to severe ulcerative colitis. In:ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US); 2000. [cited 2016 Feb9]. Available from:https://www.clinicaltrials.gov/ct2/show/NCT01240915?term=Multistem%28R%29&rank=1NLM Identifier:NCT01240915.
16. Pfizer. Pfizer pipeline; 2015 Jul 28 [cited 2016 Jan30]. Available from:http://120.52.72.39/www.pfizer.com/c3pr90ntcsf0/sites/default/files/product-pipeline/July%2028%202015%20Pipeline%20Update.pdf.
17. I.Mendel, E.Feige, N.Yacov, et al. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014;175:126–137.
18. Vascular Biogenics. Findings demonstrate potential therapeutic applicability of VB-201 in Atherosclerosis and Other Inflammatory disorders; 2013 Jul 08 [cited 2016 Feb12]. Available from:http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=1942813.
19. Vascular Biogenics. Inflammatory pipeline; [cited 2016 Feb12]. Available from:http://www.vblrx.com/inflammatory-disease-programs/inflammatory-pipline/.
20. VBL Therapeutics. VBL therapeutics presents positive phase 2 data for VB-201 in psoriasis and atherosclerosis at the late-breaking abstract session of the American Academy of Dermatology 70th annual meeting; 2012 Mar 16 [cited 2016 Feb12]. Available from:http://www.vblrx.com/vbl-therapeutics-presents-positive-phase-2-data-for-vb-201-in-psoriasis-and-atherosclerosis-at-the-late-breaking-abstract-session-of-the-american-academy-of-dermatology-70th-annual-meeting/.
21. VBL Therapeutics. VBL therapeutics reports topline results from phase 2 studies of VB-201 in psoriasis and ulcerative colitis; 2015 Feb 17 [cited 2016 Feb12]. Available from:http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2017105.
22. Cision. Interim report. 1 Jan. 2013 till 31 Mar. 2013; [cited 2016 Mar5]. Available from:http://mb.cision.com/Main/6574/9419623/126426.pdf.
23. Business wire. Neurovive pharmaceutical:topline result of phase III study of Ciclomulsion® in acute myocardial infarction expected this quarter; 2015 May 25 [cited 2016 Apr29]. Available from:http://www.businesswire.com/news/home/20150524005054/en/Neurovive-Pharmaceutical-Topline-Result-Phase-III-Study.
24. FierceBiotech. Neurovive pharmaceutical:neurovive refocuses CicloMulsion development – discontinues acute myocardial infarction indication; [cited 2016 Mar5]. Available from:http://www.fiercebiotech.com/press-releases/neurovive-pharmaceutical-neurovive-refocuses-ciclomulsion-development-disco.
25. E.Inoue, T.Ichiki, K.Takeda, et al. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. J Endocrinol. 2012;213:285–291.
26. Astellas. Financial results for 1Q/FY2015; [cited 2016 Feb29]. Available from:http://www.astellas.com/en/ir/library/pdf/1q2016_pre_en.pdf.
27. Shire. Study published in The New England journal of medicine demonstrates efficacy and favourable safety profile of Firazyr® (Icatibant) for the treatment of Hereditary Angioedema (HAE) attacks; 2010 Aug 4 [cited 2016 Feb29]. Available from:https://www.shire.com/newsroom/2010/august/study-published-in-the.
28. Shire. Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects; 2013 Nov 11 [cited 2016 Feb29]. Available from:https://www.shire.com/~/media/shire/shireglobal/shirecom/pdffiles/newsroom/2013/november/20131111-shiretoacquireviropharmarelease11.pdf.
29. Shire. Study of icatibant in japanese subjects with acute attacks of HAE; [cited 2016 Mar4]. Available from:http://www.shiretrials.com/sitecore/content/studies/clinicaltrialsen/2015/05/14/06/44/shp-fir-301?sc_lang=en.
30. G.Cao, T.P.Beyer, Y.Zhang, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011;52:2169–2176.
31. Lilly. Lilly 2012-13 corporate responsibility report; [cited 2016 Feb22]. Available from:https://www.lilly.com/_Assets/pdf/Lilly_2012_2013_CRreport.pdf.
32. Eli Lilly and Company. A study of evacetrapib in high-risk vascular disease (ACCELERATE). In:ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US); 2000. [cited 2016 Feb23]. Available from:https://www.clinicaltrials.gov/ct2/show/NCT01687998?term=NCT01687998&rank=1 NLM Identifier:NCT01687998.
33. Eli Lilly and Company. A study of evacetrapib (LY2484595) in participants with high cholesterol (ACCENTUATE). In:ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US); 2000. [cited 2016 Feb22]. Available from:https://www.clinicaltrials.gov/ct2/show/NCT02227784 NLM Identifier:NCT02227784.
34. Lilly. Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease; 2015 Oct 12 [cited 2016 Feb22]. Available from:https://investor.lilly.com/releasedetail.cfm?releaseid=936130.
35. H.P.Zhao, B.R.Xiang Discontinued cardiovascular drugs in 2013 and 2014. Expert Opin Investig Drugs. 2015;24:1083–1092.• This paper provides the data of the 11 cardiovascular drugs discontinued in 2013 and 2014.
36. H.P.Zhao, H.M.Jiang, B.R.Xiang. Discontinued drugs in 2012:cardiovascular drugs. Expert Opin Investig Drugs. 2013;22:1437–1451.
37. H.P.Zhao, H.M.Jiang, B.R.Xiang. Discontinued drugs in 2011:cardiovascular drugs. Expert Opin Investig Drugs. 2012;21:1449–1462.
38. T.Joy, R.A.Hegele. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol. 2009;24:364–371.
39. G.G.Schwartz, A.G.Olsson, M.Abt, et al. dal-OUTCOMES investigators; Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
40. D.E.Gutstein, R.Krishna, D.Johns, et al. Anacetrapib, a novel CETP inhibitor:pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91:109–122.
41. I.Kola, J.Landis. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–716.
42. J.Bailey, M.Thew, M.Balls. Predicting human drug toxicity and safety via animal tests:can any one species predict drug toxicity in any other, and do monkeys help? Altern Lab Anim. 2015;43:393–403.•• This paper stated the data and results for the question whether one species can predict drug toxicity in the other.
43. Y.Sugiyma, S.Yamashita. Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev. 2011;63:494–502.•• This paper provides an excellent review to the impact of Microdosing Clinical Study.
44. E.A.Czerepak, S.Ryser. Drug approvals and failures:implications for alliances. Nat Rev Drug Discov. 2008;7:197–198.